On January 27, 2025, the Federal Circuit held that the Patent Trial and Appeal Board (“PTAB”) “has jurisdiction over IPRs concerning expired patents.” See Apple Inc. v. Gesture Tech. Partners, LLC, 2025 WL 299939, *2 (Fed. Cir. Jan. 27, 2025).

Background and Procedural History

Apple, the inter partes review (“IPR”) petitioner, filed an IPR petition in June 2021. See id. at *1. The patent at issue was U.S. Patent No. 8,878,949 (“the ’949 patent”), related to image capture technology and owned by Gesture. See id. Apple asserted that all claims of the ’949 patent were obvious over the prior art. See id. The PTAB held that several claims of the ’949 patent were unpatentable and that others were not shown to be unpatentable. See id. Both parties appealed the PTAB’s decision to the Federal Circuit. On appeal, the Federal Circuit addressed arguments directed towards both jurisdiction and obviousness. This blog discusses only the jurisdictional portion of the court’s analysis.

Patent Owner Argues PTAB Lacks Jurisdiction over Expired Patents

At the Federal Circuit, Gesture argued “that the [PTAB] could not exercise jurisdiction over this IPR because the ’949 patent expired in May 2020, before Apple filed its petition in June 2021.” See id. at *2. Gesture relied on Oil States Energy Services, LLC v. Greene’s Energy Group, LLC, 584 U.S. 325 (2018), stating that “jurisdiction over the expired patent becomes limited to the Article III courts” because patent owners lose their exclusionary rights when a patent expires. See id. Rather, the patent owner’s rights “become[ ] limited to collecting damages that formerly existed through an infringement action in an Article III court[.]” See id. Therefore, Gesture reasoned that the PTAB did not have jurisdiction over the ’949 patent.

Federal Circuit’s Holding

Acknowledging that the Federal Circuit has not “squarely addressed whether the [PTAB] may institute IPRs for patents after they have expired[,]” the court stated affirmatively that “the [PTAB] has jurisdiction over IPRs concerning expired patents.” See id. To support its holding, the Federal Circuit relied on Oil States and the public-rights doctrine. See id. at *3. The Federal Circuit also noted that this is not the first case it has reviewed involving expired patents in an IPR decision, which implicitly shows that the PTAB has jurisdiction over expired patents. See id.

Despite its reliance on the same case, the Federal Circuit rejected Gesture’s argument. The Court summarized the Oil States holding, stating that “IPRs fall within the public-rights doctrine and do not violate Article III.” See id. (citing Oil States Energy Services, 584 U.S. at 337). The Court further emphasized the fact that although an expired patent limits a patent owner’s rights, it does not eliminate their rights. See id. For example, a patent owner of an expired patent can sue for past damages. See id. (citing Genetics Inst., LLC v. Novartis Vaccines & Diagnostics, Inc., 655 F.3d 1291, 1299 (Fed. Cir. 2011). In that light, the Federal Circuit reasoned that “Gesture fail[ed] to explain why an IPR, which ‘would have a consequence on any infringement that occurred during the life,’ of the patent, falls outside the scope of the public-rights doctrine solely because the patentee’s prospective right to exclude others has terminated.” See id. (internal citations omitted) (citing Sony Corp. v. Iancu, 924 F.3d 1235, 1238 n.1 (Fed. Cir. 2019).

Conclusion & Takeaway

With the Federal Circuit’s confirmation that the PTAB has jurisdiction to conduct IPR proceedings over expired patents, PTAB practitioners can now proceed with confidence when challenging an expired patent. Apple, Inc. v. Gesture Tech. Partners makes it clear that the PTAB has jurisdiction over IPR proceedings involving expired patents.

The Federal Circuit’s recent decision in Palo Alto Networks, Inc. v. Centripetal Networks, LLC, No. 2023-1636, 2024 WL 5114204 (Fed. Cir. Dec. 16, 2024) concerns an obviousness determination based on a motivation to combine.  Below is a discussion of the case and a key takeaway for patent practitioners and innovators.

Before the Patent Trial and Appeal Board (“PTAB”) in an Inter Partes Review, the Petitioner, Palo Alto Networks, Inc., asserted that the patent-at-issue is invalid as obvious over the prior art, arguing that one skilled in the art at the time would have had a motivation to combine two prior art references.  Palo Alto Networks, Inc. v. Centripetal Networks, LLC, No. IPR2021-01150, 19-20 (P.T.A.B. Feb. 16, 2023).  Specifically, one reference disclosed all the limitations of the patent-at-issue except one, and a second reference disclosed the absent limitation.  Id.  The Petitioner urged the PTAB to find a motivation to combine the two references because their combination reflects an “application of known techniques [] to improve similar devices [] to provide predictable results in the same way.”  Id. at 24 (internal citation omitted).

The PTAB ruled in favor of the Patent Owner, holding that the Petitioner failed to adduce a “necessary bridge showing that one of ordinary skill in the art would have appreciated” that the two prior art references could be combined to yield the inventive aspects of the patent-at-issue.  Id. at 26.  The Petitioner then appealed the PTAB’s final written decision to the Federal Circuit.

On appeal, the Federal Circuit vacated and remanded the case because the PTAB did not adequately explain why a person of ordinary skill in the art would not have had a motivation to combine the two prior art references.  Palo Alto Networks, Inc. v. Centripetal Networks, LLC, No. 2023-1636, 2 (Fed. Cir. Dec. 16, 2024).  In particular, the Federal Circuit could not “discern with any confidence what the Board meant” by “necessary bridge.”  Id. at 11.  “If the Board meant to say that it found no motivation to combine—and we do not know whether it did—it certainly failed to explain why a person of ordinary skill in the art would not have been motivated to [combine the two prior art references].”  Id.

Patent practitioners and innovators should revisit this case when deciding whether to appeal a PTAB decision to the Federal Circuit, especially if the Board’s determination turns on a motivation to combine.  Remember that the PTAB must clearly state its findings.  A final written decision that mixes analysis with ambiguous or untested terminology (i.e., “necessary bridge”) increases the likelihood of a successful appeal.

Sources:

Palo Alto Networks, Inc. v. Centripetal Networks, LLC, No. IPR2021-01150 (P.T.A.B. Feb. 16, 2023)

Palo Alto Networks, Inc. v. Centripetal Networks, LLC, No. 2023-1636, 2024 WL 5114204 (Fed. Cir. Dec. 16, 2024) 

With U.S. Patent and Trademark Office (USPTO) Director Kathi Vidal’s return to private practice in December 2024 and the future permanent Director yet to be tapped for nomination, it is a good time to reflect on one of the most impactful processes that grew during Vidal’s tenure — Director Review.  It was not until shortly before the end of Director Vidal’s term, on October 31, 2024, that the USPTO implemented 37 CFR § 42.75 and effectively codified the Interim Director Review Process. The following provides an overview of the origin of Director Review, the process as it has been codified, and a recap of the statistics under Director Vidal’s purview.

Background

Director Review was born from the Supreme Court’s decision in United States v. Arthrex, Inc., where the Court explained that “constitutional principles chart a clear course: Decisions by [administrative patent judges (APJs)] must be subject to review by the Director.” 594 U.S. 1, 24 (2021). The Court further held that “the Director has the authority to provide for a means of reviewing PTAB decisions” and “may review final PTAB decisions and, upon review, may issue decisions [themself] on behalf of the Board.” Id. at 25.

Process

Availability and Filings

A party to a Patent Trial and Appeal Board (PTAB) decision may request Director Review of any decision including Derivation Proceedings (35 U.S.C. §§ 135), inter partes review (35 U.S.C. §§ 314, 318), and post-grant review (35 U.S.C. §§ 324, 328).  The request must be filed either: (1) within 14 days of the entry of a non-final decision or a decision to institute a trial, or (2) within 30 days of the entry of a final decision or a decision not to institute a trial.  37 C.F.R. § 42.71(d).

Generally, the appellee is not permitted to respond to a request for Director Review; however, the Director may authorize such a response as well as the submission of new evidence or arguments if warranted (e.g., in cases addressing issues of first impression or issues involving intervening changes in the law or USPTO procedures, guidance, or decisions).

Determination of Whether to Grant Director Review

A request for Director Review is evaluated by the Advisory Committee, which is established by the Director and comprises at least 11 members from various USPTO business units (e.g., Office of the Under Secretary, Patent Trial and Appeal Board, Office of the General Counsel, etc.).  The Advisory Committee then provides a recommendation to the Director, who may take it into consideration along with the underlying decision and the associated arguments and evidence.

The Director may also grant review sua sponte (on the Director’s own initiative)—although it is typically reserved for issues of “exceptional importance,” which are flagged by the PTAB’s internal post-issuance review team.

 Process Following Determination

Should the Director determine to deny review, an order denying the request will be entered into the record. The Director is not required to (and generally opts not to) provide any reasons for denial.

Should the Director determine to grant review, the Director may issue an initial order granting review and identifying the issue(s) to be addressed by a later order.  Alternatively, the Director may issue a single decision that simultaneously grants Director Review and resolves the identified issue(s).

In cases where the Director remands a decision to the Board, the Board is expected to issue a new decision either by: (1) the due date specified in the Director’s remand order, or (2) absent a due date set by the Director, six months from the date of remand.

Challenging Director Review Decisions

Depending on the underlying decision subject to the Director Review order, parties may seek an appeal to the Federal Circuit.  Specifically, a party may appeal a Director Review decision of a final, rehearing, or other appealable decision under 35 U.S.C. §§ 135 (derivation proceeding), 316 (IPR), or 328 (PGR). Conversely, Director Review decisions of Board decisions on institution are not appealable. See 35 U.S.C. § 314(d).

In the alternative, a party may file one request for rehearing a Director Review Decision.  However, such a request must specifically identify what matter the Director Review decision overlooked and may not serve as an opportunity to raise new issues or arguments.

Director Review under Director Vidal

The following chart provides a breakdown of Director Review under Director Vidal (as of Dec. 15, 2024, available at https://www.uspto.gov/patents/patent-trial-and-appeal-board/status-director-review-requests):

In sum, Director Vidal faced 332 requests for Director Review during her two-and-a-half-year tenure. At a high-level, it is evident that Petitioners have had greater success in receiving grants to requests for Director Review– as opposed to their counterpart Patent Owners — 21.2% grant rate compared to a 1.48% grant rate (dismissed, withdrawn, and pending not considered).  Additionally, Director Vidal notably took the initiative to conduct Director Review sua sponte in 36 cases, begging the question of whether the future Director will similarly take the onus to review without a party’s invitation. 

With the number of requests growing year by year and the recent codification of Director Review, Patent Owners and Petitioners alike may feel encouraged to continue to request Director Review—even in the face of limited success rates as shown above.  But, with Director Vidal’s stepping down, one may only guess how the future Director will wield the power of Director Review. 

See generally 37 CFR § 42.75; see also https://www.uspto.gov/patents/ptab/decisions/director-review-process.

The recent decision by the Federal Circuit in Honeywell International Inc. v. 3G Licensing, S.A., issued on January 2, 2025, overturned the Patent Trial and Appeal Board’s (“the Board”) factual and legal holdings in the final written decision of IPR2021-00908. In this article, we delve into the court’s holding and its impact on upcoming patent disputes.

Background: The ’718 Patent and the PTAB’s Decision

At the center of this case was U.S. Patent No. 7,319,718 (“the ’718 patent”)[1], which relates to coding Channel Quality Indicator (CQI) signals in mobile communication systems. These signals enable cellular base stations to adjust data rates dynamically based on the quality of the connection reported by user devices. Claim 1 of the ’718 patent recites:

Honeywell International Inc. (Honeywell) filed a petition for inter partes review (IPR) challenging the claims of the ’718 patent as being unpatentable as obvious over the Philips reference. The sequence table (above) recited in claim 1 of the ’718 patent is disclosed by the Philips reference except for the last two bits in the last row, which are flipped. The Board ultimately declined to hold any of the challenged claims unpatentable as obvious despite acknowledging the single difference between the Philips reference and the claimed invention.

Federal Circuit’s Critique and Reversal

The Federal Circuit reversed the Board’s decision, finding significant legal and factual errors. Judge Dyk’s majority opinion focused on four key areas where the Board went astray:

1. Misapplication of Motivation to Modify

The Board erred by overemphasizing the ’718 patent inventor’s stated goal of maximizing system throughput. The Federal Circuit clarified that the motivation to modify prior art does not have to be the same as the inventor’s purpose. Instead, any motivation recognized in the technical field, such as the Philips reference’s emphasis on most significant bit (MSB) protection, is sufficient to establish obviousness.

2. Ignoring Clear Teachings of Prior Art

The Federal Circuit held that a person of ordinary skill in the art would find it obvious to swap two bits in the basic sequence of the Philips reference. The Board’s failure to adequately consider these teachings undermined its conclusion.

3. Conflation of Obviousness and Anticipation

The Board’s analysis improperly conflated the standards for obviousness and anticipation. By focusing on whether the Philips reference disclosed the exact modification claimed in the ’718 patent, the Board applied a standard closer to anticipation. The Federal Circuit reiterated that obviousness does not require an identical disclosure and the Board committed legal error by deviating from the invalidity theory set forth in the petition.

4. Overemphasis on Industry Consensus

The Board’s reliance on a lack of industry consensus was misplaced. The Federal Circuit emphasized that obviousness does not require a proposed solution to be the preferred or most popular approach. Instead, the question is whether the modification was desirable in light of the prior art.

Tips for Patent Practitioners

In light of the Honeywell decision, patent practitioners should consider emphasizing the legal standard in their petitions and patent owner responses. The Board may not always apply the correct legal standards, and reusing a statement of the law from a previous filing may not be sufficient. A practitioner should consider tailoring their discussion of the legal standard to their specific case and ensure it is supported by more recent decisions, such as Honeywell


[1] Available at https://patents.google.com/patent/US7319718B2/en?oq=.+7%2c319%2c718

At the end of each fiscal year running from October 1 through September 30, the Patent Trial and Appeal Board (“PTAB”) provides a summary of its trial statistics. [1] This information provides practitioners with useful insight into trends at the PTAB regarding petitions filed, institution rates, and outcomes. This blog post highlights the statistics and trends at the PTAB for Fiscal Year 2024 (“FY24”).

Petitions Filed

In FY24, 1,288 petitions were filed. Out of these petitions, 97% were for inter partes review (“IPR”) and 3% were for post grant review (“PGR”). [2] Additionally, the PTAB categorized the petitions filed by technology, which showed: 69% electrical/computer, 22% mechanical and business method, 6% bio/pharma, 3% chemical, and less than 1% design. [3]

The FY24 trends for petitions filed were consistent with the trends over the last three years. In FY23, 98% of petitions filed were for IPRs and 2% were for PGRs. The petitions filed sorted by technology for FY23 were categorized as: 69% electrical/computer, 20% mechanical and business method, 7% bio/pharma, 3% chemical, and 0% design (although 5 design petitions were filed). [4] In FY22, 97% of petitions filed were for IPRs and 3% were for PGRs. The petitions filed sorted by technology for FY22 were categorized as: 65% electrical/computer, 23% mechanical and business method, 7% bio/pharma, 4% chemical and 0% design (although 6 design petitions were filed). [5] In FY21, 93% of petitions filed were for IPRs and 7% were for PGRs. The petitions filed sorted by technology for FY21 were categorized as: 65% electrical/computer, 23% mechanical and business method, 7% bio/pharma, 6% chemical, and 0% design (although 3 design petitions were filed). [6]

Institution Rates

In general, it is helpful for PTAB practitioners to understand the institution rate trends to best advise their clients. However, it is particularly helpful to know the institution rates by technology. Institution rates alone cannot determine the outcome of a petition or patent at the PTAB, but it is one of many factors that may be considered.

In FY24, 68% of petitions were instituted. According to the PTAB, 740 petitions were instituted and 347 petitions were denied institution. [7] When assessing the institution rates by patent, the data showed that 74% of patents were instituted. Specifically, 650 patents were instituted and 229 patents were denied institution. [8] This was a 6% higher institution rate than by petition.

The PTAB also provided data for the institution rates by the type of technology. Although bio/pharma accounted for only 6% of the total petitions filed, 73% of bio/pharma petitions were instituted. Electrical/computer and mechanical and business method technologies also resulted in institution rates of greater than 50% at 69% and 66%, respectively. Chemical petitions had an institution rate of 46% and design petitions had a 0% institution rate. [9]

Outcomes

1,212 petitions reached an outcome  at the PTAB between October 1, 2023 and September 30, 2024. Out of the total petitions, approximately 38% (446 petitions) reached final written decisions. Out of those that reached final written decisions, 26% (312 petitions) of the total petitions were all unpatentable, 6% (67 petitions) were all patentable, and 6% (67 petitions) were a mix of patentable and unpatentable. Additionally, 28% (338 petitions) were denied institution, 32% (387 petitions) settled, 2% (19 petitions) requested adverse judgment, and 2% (22 petitions) were dismissed. [10]

Source: The data for this chart can be found at https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2024__roundup.pdf

Similar outcomes were reported for outcomes sorted by patents. There were 1,037 patents that reached an outcome at the PTAB between October 1, 2023 and September 30, 2024. Out of the total patents, approximately 39% (416 patents) reached final written decisions. Out of those that reached final written decisions, 27% (284 patents) of the total patents were all unpatentable, 6% (67 patents) were all patentable, and 6% (65 patents) were a mix of patentable and unpatentable. Additionally, 24% (252 patents) were denied institution, 30% (312 patents) settled, 2% (16 patents) requested adverse judgment, 2% (17 patents) were dismissed, and 2% (24 patents) had mixed outcomes. [11]

Source: The data for this chart can be found at https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2024__roundup.pdf

The PTAB also provided statistics for outcomes sorted by claims challenged. In FY24, there were 17,827 claims challenged. Out of the total claims challenged, approximately 38% (6,891 claims challenged) reached final written decisions, where 30% (5,400 claims challenged) of the total claims challenged were unpatentable and 8% (1,491 claims challenged) were patentable. Additionally, 24% (4,355 claims challenged) were denied institution, 31% (5,603 claims challenged) were challenged but did not reach a final written decision, 4% (766 claims challenged) were disclaimed, and 1% (212 claims challenged) were dismissed. [12]

Source: The data for this chart can be found at https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2024__roundup.pdf

The statistics show that less than 50% of petitions, patents, or claims challenged reached a final written decision at the PTAB. Of the less than half that did reach a final written decision, a significant percentage were all unpatentable. For example, 416 patents reached a final written decision. Out of the 416 patents to reach a final written decision, approximately 68% of patents were all unpatentable and only about 16% were all patentable.

Additionally, there has been a slight upward trend over the past few years for all unpatentable patents with a final written decision, with the trend appearing to begin to level out from FY22 to FY24. The percentage of total patents to reach an outcome with a final written decision of all unpatentable was 27% in FY24, 28% in FY23, 26% in FY22, 17% in FY21, 24% in FY20, and 20% in FY19. [13]

Conclusion

Overall, the most recent trends at the PTAB provide practitioners with useful information. For example, although bio/pharma petitions accounted for only 6% of total petitions filed, the PTAB’s statistics show that the bio/pharma petitions had the highest institution rates. Similarly, 46% of chemical petitions were instituted despite making up only 3% of total petitions filed. This information may be useful for practitioners assessing the likelihood of success for institution, depending on the technology.

However, the trends for outcomes show that only a small percentage of patents are upheld in whole (6%) or in part (6%). For patent owners, this indicates a lower likelihood of success at the PTAB. Additionally, the success rate for patent owners appears to be on a downward trend, based on the data from recent years. On the other hand, the same data shows that 27% of patents are unpatentable, which indicates a comparatively higher likelihood of success for patent challengers. Ultimately, it is important for PTAB practitioners to understand the most recent PTAB trends to provide the best representation for their clients because the data has the potential to inform both strategy and risk analysis.

More information about the PTAB’s trial statistics for FY24 may be found at: https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2024__roundup.pdf.

Sources:

[1] See Statistics, USPTO, https://www.uspto.gov/patents/ptab/statistics (last visited Dec. 26, 2024).

[2] See PTAB Trial Statistics FY24 End of Year Outcome Roundup IPR, PGR, USPTO, 3 https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2024__roundup.pdf (last visited Dec. 20, 2024).

[3] See id. at 4.

[4] See PTAB Trial Statistics FY23 End of Year Outcome Roundup IPR, PGR, USPTO, 3-4, https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2023__roundup.pdf (last visited Dec. 20, 2024).

[5] See PTAB Trial Statistics FY22 End of Year Outcome Roundup IPR, PGR, USPTO, 3-4, https://www.uspto.gov/sites/default/files/documents/ptab__aia_fy2022_roundup.pdf (last visited Dec. 20, 2024).

[6] See PTAB Trial Statistics FY21 End of Year Outcome Roundup IPR, PGR, USPTO, 3-4, https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2021__roundup.pdf (last visited Dec. 20, 2024).

[7] See supra, PTAB Trial Statistics FY24 End of Year Outcome Roundup IPR, PGR, at 6.

[8] See id. at 7.

[9] See id. at 8.

[10] See id. at 10.

[11] See id. at 11.

[12] See id. at 12.

[13] See id. at 11 (providing FY24 percentage); see also supra PTAB Trial Statistics FY23 End of Year Outcome Roundup IPR, PGR at 11 (providing FY23 percentage); supra PTAB Trial Statistics FY22 End of Year Outcome Roundup IPR, PGR at 12 (providing FY22 percentage); supra PTAB Trial Statistics FY21 End of Year Outcome Roundup IPR, PGR at 12 (providing FY21 percentage); PTAB Trial Statistics FY20 End of Year Outcome Roundup IPR, PGR, USPTO, 14, https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2020_roundup.pdf (last visited Dec. 26, 2024) (providing FY20 percentage); PTAB Trial Statistics FY19 End of Year Outcome Roundup IPR, PGR, USPTO, 14, https://www.uspto.gov/sites/default/files/documents/ptab_aia_fy2019_roundup.pdf (last visited Dec. 26, 2024) (providing FY19 percentage).

At the end of October, the U.S. Patent Trial and Appeal Board (“PTAB”) issued a final written decision in PGR2023-00023, finding all claims of a patent owned by Halliburton Energy Services unpatentable under 35 U.S.C. § 101.

Profrac Holding Corp and U.S. Well Services, LLC filed a petition for post grant review of all claims of U.S. Patent No. 11,373,058 (“the ’058 patent”) which is directed towards systems and methods for operating an electric fracking pump. Claim 1 recited a computer-implemented method for controlling electrical fracturing equipment for fracturing a well, and the method comprising the following steps:

  1. generating a sequence of stimuli for application to a well environment, the sequence of stimuli comprising one or more of particulate concentrations, chemical concentrations, or a pump rate control;
  2. receiving formation response data comprising data from one or more downhole sensors or surface sensors;
  3. selecting a representative system model based on the received formation response data and sequence of stimuli; and
  4. controlling an electrical fracturing pump based on the representative system model.

The PTAB applied the U.S. Supreme Court’s two-part framework of Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 575 U.S. 208 (2014) in conjunction with the USPTO’s Section 101 Guidance. At the first step, the PTAB had to determine whether the claims were directed to one of the four statutory categories of patentable subject matter under § 101. Based on the language of the claim, the PTAB determined that the claims were directed to a process. At the second step of the framework, the PTAB broke down the analysis into two parts with part A having two prongs. At prong one of step 2A, the PTAB had to determine whether the claims recite an abstract idea. The PTAB found that the steps of “receiving formation response data comprising data from one or more downhole sensors or surface sensors” and “selecting a representative system model based on the received formation response data and sequence of stimuli” constituted mental processes. See PGR2023-00023, Paper 26 at 9 (P.T.A.B. Oct. 29, 2024). Looking to the background of the ’058 patent, the PTAB held that the patent teaches that “a technician may review sensor data” and that the representative system model is “typically manually selected by a technician based on observed sensor data.” Id. at 10. With respect to the “controlling” step, the PTAB agreed with the Patent Owner that it is not a mental step. However, the PTAB noted that the patent explains that the “generating” and “controlling” steps can be performed via a generic computer. Id. at 11. The PTAB therefore found that the claims were directed to an abstract idea.

Under step 2a prong two, the PTAB had to determine whether the claims recite additional elements that integrate the abstract idea into a practical application. The PTAB concluded that the “generating” and “controlling” steps do no more than link the abstract idea to a technical field. Id. at 13. The Patent Owner characterized the advantage of the ’058 patent as the “selection of a representative system model that more accurately reflects the well to which it is applied, thereby improving fracturing operations.” Id. The Patent Owner further argued that the patent solves a problem in the field by “providing techniques for optimizing well treatments using representative system models selected according to formation responses to stimuli indicated by sensor data.” Id. at 14. The PTAB disagreed with the Patent Owner and found that the Patent Owner’s arguments supported finding that the mental process steps are the focus of the claimed advance of the patent and that “the other steps do not integrate the exception into a practical application, but rather apply it to a technical field.” Id. at 14. The PTAB found that the “controlling” step does not add meaningful limitations but instead “simply applies the selected representative system model to a pump.” Id. at 15.

The PTAB then moved on to part B of step 2 which required it to determine whether the claims add a specific limitation beyond the abstract idea that is not “well-understood, routine [and] conventional” in the field. Id. (quoting 2019 Revised Guidance, 84 Fed. Reg. at 56). Relying on the background of the patent, the PTAB agreed with the Petitioner that “it will be understood that much of claim 1 was well-understood, routine, and conventional, whether considered individually or as an ordered combination.” Id. at 16. The PTAB explained that the patent makes clear that “adjusting settings on an electrical fracturing pump” is what the patent “teaches to generate a sequence of stimuli.” Id. The PTAB then concluded that the claims of the patent were directed to an abstract idea without something more and are therefore unpatentable.

The PTAB went on to explain that its decision is supported by the Federal Circuit decision in TDE Petroleum Data Sols., Inc. v. AKN Enter., 657 F. App’x 991 (Fed. Cir. 2016) because, like in TDE Petroleum, the PTAB found that the “receiving” and “selecting” steps of the present claims are “‘ordinary steps of data analysis’ that merely involve ‘collecting information’ and ‘analyzing it.’” PGR2023-00023, Paper 26 at 19 (quoting TDE Petroleum Data Sols., Inc., 657 F. App’x at 993). The PTAB disagreed with the Patent Owner that the claims are closely analogous to the claims found patent eligible by the Federal Circuit in EcoServices, LLC v. Certified Aviation Servs., LLC, 830 Fed. App’x 634 (Fed. Cir. 2020). The PTAB explained that the claims in EcoServices are distinguishable because they were directed to physical hardware whereas the present claims did not include any physical hardware.

The PTAB’s decision in this case presents another example of how the Board continues to navigate Section 101 challenges and apply the USPTO’s framework. The PTAB’s decision further highlights the critical role that patent specification plays in a § 101 analysis. The PTAB looks to the specification to confirm the technological advance of the claims. As evidenced by the PTAB’s decision, the specification can be used to prove patent eligibility just as much as it can be used to disprove it. When drafting applications, patent applicants should pay particular attention to the background section and should be careful in how they describe the technological field or prior art. If the specification admits that some of the claim elements are well-understood or routine in the art, the patent applicant could face difficulties in opposing a §101 rejection or challenge. Patent applicants should also be specific in how they describe the advances and inventiveness of their claimed invention and should include details of how the applicant’s technological solution is implemented.

Furthermore, for patent owners facing a § 101 challenge at the PTAB, this decision demonstrates the importance of how a patent owner characterizes their claimed invention or the improvements their invention provides. Here, the PTAB found that the way the Patent Owner characterized the claimed advance of its patent in its Patent Owner Response “show[ed] why the[] additional elements do not do anything more than link the judicial exception to the technical field.” PGR2023-00023, Paper 26 at 13. In light of this decision, Patent Owners should be careful in their word choice when describing their claimed invention and should strategize ways on how best to present their claimed technological advances to the PTAB.

The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act was introduced on June 22, 2023, with the aim to reform the U.S. Patent Trial and Appeal Board (PTAB).  The PREVAIL Act serves as a supplement to the proposed STRONGER Patents Act, introduced in 2019.

The drafters have identified three key goals of the PREVAIL Act:[1]

  1. Restore fairness to the PTAB to promote innovation and competitiveness.
  2. Improve PTAB rules to protect inventors from costly, unnecessary litigation.
  3. Ensure UPSTO has resources it needs to administer a patent system that promotes innovation.

First, the PREVAIL Act aims to “restore fairness” by altering the requirements of challenges before the PTAB. Currently, there is no standing requirement under the IPR statute, allowing third parties to file requests for IPRs independent of infringement allegations.[2]  The drafters identify this as a potential loophole which may be exploited to force patent owners to defend against unlimited challenges. Therefore, the Act would explicitly require challengers to have been sued or threatened with a patent infringement lawsuit prior to filing a PTAB challenge. Additionally, the Act proposes establishing a rebuttable presumption against joinder for a time-barred party—i.e.,  a party that did not raise a PTAB challenge within one year of being sued for patent infringement is prohibited from joining a PTAB proceeding brought by another party.  The drafters have also identified multiple petitions as a source of increased cost to patent owners.  Accordingly, the Act has been drafted to require a party to raise all arguments in one challenge before the PTAB.  In practice, this proposed change may create an issue with respect to the length limitations of petitions.  Given the technical complexity of many patents, challengers require extensive explanations to present arguments sufficient for institution, and, therefore, multiple petitions can be useful.  Thus, if the proposed change is adopted, the USPTO may need to reconsider its current word limit.  With respect to the PTAB’s analysis of instituted challenges, the Act proposes changing the burden of proof for invalidity from a “preponderance of the evidence” standard to district courts’ “clear and convincing” standard.  Further, the drafters believe that PTAB proceedings require more transparency and, therefore, the Act requires the USPTO Director to issue separate written opinions when rehearing PTAB decisions and prohibits the Director from influencing PTAB panel decisions.  While it may be a stretch to presume the Director “meddl[es] in a PTAB panel’s decision” simply because there are no express rules preventing such, it may be beneficial to all patent owners and potential challengers to have the Director’s written opinions publicly available.[3] 

Second, the Act intends to prevent unnecessary litigation and the associated costs.  A majority of PTAB proceedings—at least 85% according to the Act—have co-pending proceedings in other forums (e.g., federal district court).  While the drafters believe that patent challengers “get several bites at the apple” (i.e., able to raise duplicative challenges in both forums), this is slightly misguided as a district court commonly stays the case pending a PTAB decision and any decided upon arguments (and sometimes unraised arguments) are estopped from being brought again before the district court.[4]  Granted, district courts are inconsistent as to the application of IPR estoppel, requiring the Federal Circuit to weigh in on a consistent basis.[5]  Moreover, estoppel of the challenger’s arguments does not inherently reduce the overall litigation costs.  Thus, the PREVAIL Act proposes requiring a party to explicitly choose between making the validity challenges before the PTAB or another forum.  Additionally, the Act requires a party that is already involved in a separate proceeding to expressly agree not to pursue their PTAB petition claims in the other forum.  To further limit litigation costs and prevent judicial inefficiency, the Act proposes that the PTAB is required to deny any petition or dismiss a proceeding if another forum has already upheld the validity of the patent at issue.  Also, the Act would require the PTAB to reject any proposed challenge or request to reexamine a patent when the underlying arguments have previously been considered by the USPTO.  To this point, it is unclear whether an examiner’s considerations during prosecution will be sufficient to trigger this automatic bar.

Lastly, the Act aims to rectify some of the Patent Office’s financial concerns and support small businesses.  The drafters have surmised that approximately $409.8 million in user fees have been diverted from the Patent Office.  Accordingly, the Bill proposes the elimination of fee diversion to other federal agencies and programs by establishing a new revolving fund in the U.S. Treasury to ensure the Patent Office has sufficient funding for timely and quality examination.  The Bill also hopes to address financial concerns at the other end of prosecution as small businesses may not always have the resources needed to successfully navigate the patent system.  The PREVAIL Act would require the Small Business Administration to draft two reports examining the impact of patents and abusive demand letters on small businesses.  Moreover, the Bill is drafted to expand access to patent-searching databases currently available only in-person at public search facilities.

In sum, the PREVAIL Act proposes numerous changes that may increase the efficiency of PTAB proceedings while remedying financial concerns for both the USTPO and patent owners.  However, it may be necessary to rein in some of the requirements that potentially alter the functionality of raising a challenge before the PTAB.  If patent challengers are restricted to the point where an action before the PTAB becomes less desirable than an invalidity challenge in another forum, then the overall purpose of the PTAB is lost.

Patent owners and challengers should not hold their breath waiting for the Act to come into effect nor should they proceed differently in anticipation of the proposed changes to the PTAB process.  The STRONGER Patents Act (which the PREVAIL Act intends to supplement) has remained dormant since its introduction as a bill in July 2019.[6]  Comparably, the text of the Prevail Act has yet to be submitted to the Library of Congress;[7] thus, the Act is in its infancy and will likely grow into a different form should it become law. 


[1] Prevail Act Fact Sheet, https://www.coons.senate.gov/download/prevail-act-fact-sheet

[2] See 35 U.S.C. § 311.

[3] Prevail Act Fact Sheet.

[4] Id.

[5] See, e.g., Ironburg Inventions Ltd. v. Valve Corp., 64 F.4th 1274 (Fed. Cir. 2023).

[6] See Stronger Patents Act of 2019, S. 2082, 116th Cong. § 1 (2019). https://www.congress.gov/bill/116th-congress/senate-bill/2082/text (as of 7/10/2023)

[7] A bill to amend title 35, United States Code, to address matters relating to patent subject matter eligibility, and for other purposes, S.2140 , 118th Cong. (2023). https://www.congress.gov/bill/118th-congress/senate-bill/2140/actions?s=3&r=1&q=%7B%22search%22%3A%5B%22Coons%22%5D%7D (as of 7/10/2023)

The food tech industry has grown rapidly in the last ten years due to innovations in the alternative animal product space and a growing customer desire for more sustainable options.[1] With this rapid growth and an increasing number of entrants to the field comes an increased likelihood of intellectual property clashes. In this article, we will discuss the IPR petitions that Motif FoodWorks Inc. (“Motif”) filed against competitor Impossible Foods Inc.’s (“Impossible Foods”) patents and the PTAB’s recent decision to institute inter partes review (IPR) for U.S. Patent No. 9,943,096 B2.

Background

Impossible Foods is one of the early entrants to the food tech industry and has a large global patent portfolio. The heart of Impossible Food’s portfolio are hemeproteins.[2] Motif is a Massachusetts-based start-up that recently launched an alt-meat burger using an ingredient named HEMAMI—a hemeprotein that is identical to bovine myoglobin.[3] Both companies use “precision fermentation,” a process that uses a genetically engineered microbe such as yeast, fungi, bacteria or algae to produce more sustainable ingredients.

Before Motif filed its IPR petitions, Impossible Foods filed the first U.S. patent infringement lawsuit in the food tech industry against Motif, in March 2022.[4] Impossible Foods initially accused Motif of infringing U.S. Patent No. 10,863,761 (“the ’761 patent”), covering a beef-replica product containing hemoproteins.[5]

In July 2022, Impossible Foods filed a First Amended Complaint, which added allegations that Motif infringed four additional Impossible Foods patents: U.S. Patent No. 9,943,096 (“the ’096 patent”); U.S. Patent No. 10,039,306 (“the ’306 patent”); U.S. Patent No. 11,013,250 (“the ’250 patent”); and U.S. Patent No. 11,224,241 (“the ’241 patent”).[6] In September 2022, Impossible Foods filed a Second Amended Complaint, which added allegations that Motif infringed two more patents: U.S. Patent No. 10,273,492 (“the ’492 patent”) and U.S. Patent No. 10,689,656 (“the ’656 patent”).[7]  

The IPR Petitions

After Impossible Foods filed its complaint in district court, Motif filed a petition for IPR with the PTAB on April 20, 2022, challenging the ’761 patent named in Impossible Foods’ First Complaint. That petition (IPR2022-00887) was not instituted.[8]

Subsequently, after Impossible Foods filed its First and Second Amended Complaints in the district court case, Motif filed several additional petitions for IPR with the PTAB. The new IPR petitions challenge six additional Impossible Foods’ hemeprotein patents.

In December 2022, Motif filed four IPR petitions against Impossible Foods’ patents related to meat alternative products containing hemeprotein, sugars, and sulfur compounds and methods for its use.[9] The challenged patents are the ’096 patent; the ’306 patent; the ’250 patent; and the ’241 patent. Motif argued that these patents should be revoked.[10] Furthermore, Motif argued that this concept cannot be patented in light of prior art because these components have been known to be associated with the taste and smell of meat in the food industry and have been used to simulate meat flavors in meat alternative products by food scientists and flavor chemists before Impossible Foods.[11] In April, Impossible Foods submitted a request to correct the priority claims of the ’096, ’241, ’250, and ’306 patents, claiming that these challenged patents claim the filing date of U.S. Provisional Application 61/671,069 (“the ’069 provisional”), International Application PCT/US2012/046560 (“Brown,” one of Motif’s listed prior art against several of the challenged patents), and U.S. Provisional Application 61/572,205 (“the ’205 provisional”).[12]  The corrected priority, if granted would have affected review of the ’096 and ’241 patents because Motif has argued that the subject matter of certain challenged claims of those patents were disclosed by Brown.[13] After reviewing Motif’s petition, Impossible Foods’ response, exhibits submitted by both sides, and Impossible Foods’s request to correct priority claims, the PTAB concluded that “Petitioner has not shown a reasonable likelihood that it will prevail in showing that at least one of the challenged claims is unpatentable…”[14] for three of the four IPR petitions that Motif filed. However, on June 16, 2023, the PTAB issued its decision “that Petitioner has demonstrated a reasonable likelihood of prevailing with respect to at least one challenged claim of the ’096 patent,” and instituted an IPR to examine the ’096 patent.[15]  

The ’096 patent is titled “Methods and Compositions for Affecting the Flavour and Aroma Profile of Consumables.” Regarding the priority dispute, the PTAB concluded that “[f]or purposes of this Decision on Institution, we determine that Petitioner presents sufficient evidence indicating the ’816 Provisional’s disclosure lacks written description support for the full scope of the challenged claims of the ’096 patent…. Accordingly, for purposes of this Decision, the earliest effective filing date that the ’096 patent claims are entitled to claim is …July 12, 2013.”[16] This decision means that Brown will be viewed as prior art against the ’096 patent during the IPR proceedings. Regarding claim construction, the PTAB pointed to “food flavor additive composition” as a term that will be construed during the course of the IPR proceedings.[17] Finally, the PTAB concluded that Motif has established a reasonable likelihood of prevailing on some of its asserted grounds, which is sufficient to institute review of “all challenged claims and on all grounds presented” under SAS Inst. Inc. v. Iancu.[18]

Takeaways

The PTAB’s recent decision show that the ongoing fight between Motif and Impossible Foods is just getting started and that the food tech industry should pay close attention to PTAB decisions as companies in this space continue to develop their patent portfolio.

Furthermore, the ’096 patent may not be the only Impossible Foods patent to be reviewed by the PTAB. In January 2023, Motif filed two more IPR petitions against Impossible Foods’ patents related to its plant-based alt-meat products.[19] The patents at issue in these petitions are the ’492 patent and the ’656 patent, which relate to genetically modified yeast cells.[20] The PTAB’s decision regarding institution of IPR proceedings for the ’492 patent and the ’656 patent are currently pending. We will continue to monitor developments in the Motif-Impossible Foods IPR proceedings and provide insight and updates as they become available.

[1] See e.g. Good Food Institute, https://gfi.org/blog/2023-outlook-the-state-of-the-plant-based-meat-category/ (last visited May 9, 2023). See also, a previous article we wrote profiling some companies operating in this space.

[2] See, e.g., U.S. Patent No. 10,172,381 (filed Oct. 18, 2017) and U.S. Patent No. 10,273,492 (filed Aug. 16, 2017).

[3] See, e.g. Motif, https://madewithmotif.com/2021/12/08/motif-foodworks-announces-the-commercial-launch-of-hemami-food-tech-earns-generally-recognized-as-safe-gras-status-from-fda/ (last visiting May 9, 2023).

[4] Complaint at 7-11, Impossible Foods Inc. v. Motif FodWorks Inc., No. 1-22-cv-00311 (D. Del. Mar. 9, 2022), ECF No. 1. See also a previous article we wrote covering that litigation.

[5] See Answer at 6, Impossible Foods Inc. v. Motif FoodWorks Inc., No. 1-22-cv-00311 (D. Del. Mar. 9, 2022), ECF No. 10.

[6] First Amended Complaint, Impossible Foods Inc. v. Motif FoodWorks Inc., No. 1-22-cv-00311 (D. Del. Mar. 9, 2022), ECF No. 19.

[7] Second Amended Complaint, Impossible Foods Inc. v. Motif FoodWorks Inc., No. 1-22-cv-00311 (D. Del. Mar. 9, 2022), ECF No. 22.

[8] See Institution Decision, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2022-00887 (PTAB Apr. 20, 2022).

[9] U.S. Patent No. 9,943,096 (filed Apr. 17, 2018); U.S. Patent No. 10,039,306 (filed Jul. 10, 2015); U.S. Patent No. 11,013,250 (filed Jan. 3, 2019); and U.S. Patent No. 11,224,241 (“the ’241 patent”)

[10] See IPR2023-00206, IPR2023-00209, IPR2023-00208, and IPR2023-00207

[11] See, e.g. Amended Petition, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2022-00887 at 1-3 (PTAB Dec. 7, 2022).

[12] Patent Owner’s Motion Pursuant to 37 C.F.R. §1.323, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2023-00206, 2-3 (PTAB Apr. 13, 2023).

[13] See, e.g Patent Owner’s Motion Pursuant to Board Order, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2023-00206, 3-11 (PTAB Jun. 1, 2023).

[14] See, e.g. Institution Decision, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2023-00209 at 23 (PTAB Dec. 7, 2022).

[15] See, e.g. Institution Decision, Motif FoodWorks Inc. v. Impossible Foods Inc., IPR2023-00209 at 39 (PTAB Dec. 7, 2022).

[16] Id. at 11-12.

[17] Id. at 15.

[18] See SAS Inst. Inc. v. Iancu, 138 S. Ct. 1348, 1351 (2018) (“When the Patent Office institutes an inter partes review, it must decide the patentability of all of the claims the petitioner has challenged.”)

[19] See IPR2023-00321, IPR2023-00322, and IPR2023-00206

[20] See U.S. Patent No. 10,273,492 (filed Aug. 16, 2017) and U.S. Patent No. 10,689,656 (filed Nov. 10, 2017).

In Intel Corporation v. Pact XPP Schweiz AG, the Court of Appeals for the Federal Circuit (“Federal Circuit”) reversed and remanded the decision of the Patent Trial and Appeal Board (“Board”). In the decision, the Federal Circuit rejected the Board’s rigid application of the “motivation-to-combine” analysis that required an element from one reference must provide an improvement to another reference to justify the combination. Instead, the Federal Circuit held that the “motivation-to-combine” analysis simply required showing that a proposed combination would help resolve an issue and be within the capabilities of a person of ordinary skill in the art (“POSITA”).

Background

Intel Corporation (“Intel”) petitioned for inter partes review (IPR) of claims 4 and 5 of U.S. Patent No. 9, 250, 908 (“the ’908 patent”) held by Pact XPP Schweiz AG (“PACT”).  Claim 4 of the ’908 patent taught a multiprocessor system that used a separated cache and interconnect system that interconnected each of the separated cache segments with each of the processors, each of the processors with neighboring processors, and each of the separated cache segments with neighboring separated cache segments.

Intel argued that it would have been obvious to a POSITA to combine two prior art references (“Kabemoto”) and (“Bauman”) to teach all the limitations of claim 4 under a “known-technique” rational. In particular, Intel reasoned that a POSITA “would have naturally turned to Bauman’s segmented cache to use … in Kabemoto: since Bauman’s separated cache was known to address the same cache-coherence issue that Kabemoto also sought to address.”

PACT did not dispute that the combined references disclosed all the limitations of the ’908 patent, but instead argued that Intel had failed to show that a POSITA would have been motivated to combine the references.

The Board concurred: “If … Kabemoto already addresses [the] problem through the use of a known technique similar to that of Bauman’s, [it] fail[ed] to see why one of ordinary skill in the art would regard Bauman’s technique as an obvious improvement to Kabemoto.”

Thus, the Board, in its final written decision, agreed with PACT that Intel had failed to show a proper motivation to combine the prior art.

Discussion

On appeal, Intel argued the Board’s determination that there was no motivation to combine the teachings of Kabemoto and Bauman to reach the limitations of claim 4 lacked substantial evidence; the Federal Circuit agreed holding that the Board had misapplied the standard.

Under the “known-technique” rational, “if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious unless its actual application is beyond his or her skill.” Accordingly, the Federal Circuit held that a proposed combination does not have to be the best option but can merely be a suitable option in order to satisfy a “motivation-to-combine” analysis.

Thus, Intel never had to show that replacing Kabemoto’s secondary cache with Bauman’s secondary cache constituted an improvement. Rather, it was sufficient for Intel to show that there was a known problem of cache coherency in the art, Bauman’s secondary cache helped address the issue, and combining the teachings of Kabemoto and Bauman was not beyond the capabilities of a POSITA. Accordingly, the Federal Circuit reversed the Board’s factual findings and remanded to the Board to address any remaining dispute about the patentability of claim 5.

Key Takeaways

A “motivation-to-combine” analysis does not require showing the combination constitutes an “improvement.” All that is required to be shown is that the combination could help address an issue and is within the scope of a person of ordinary skill in the art.

It seems as if Netflix and Hulu are continuously pumping out new content in their endless battle to win over more monthly subscribers.  However, when a third-party asserts patents covering streaming technology against both streaming giants, the competitors find themselves on the same side of the line.

Such was the case in an inter partes review (IPR) filed by both Netflix and Hulu petitioning U.S. Patent No. 10,225,588 (“the ’588 Patent”), assigned to DivX.  The streaming companies claimed that the ’588 Patent was unpatentable due to obviousness.  Specifically, the petitioners argued that a “relevant artisan” would have combined three prior art patents to address the “piracy concerns, improve the efficiency of adaptive streaming, optimize the balance between bitrate and bandwidth, and improve the end-user experience with fast startup and seek,” as required by the claim limitations in the ’588 Patent. But the Board disagreed—ruling that the petitioners failed to prove the patent obvious because they did not show that an artisan would have had a “reasonable expectation of success” in combining the proposed prior art to arrive at the same system claimed in the ’588 Patent.[1]

Netflix and Hulu appealed the PTAB’s decision to the Federal Circuit, and the Court agreed that the PTAB “committed a fundamental legal error in defining the combination it was evaluating.”  Specifically, the Court found that PTAB committed two errors: (1) failure to adhere to the principle that the petitioner’s contentions “define the scope of the litigation all the way from institution through to conclusion” and (2) the prior art reference must consider everything that it teaches and is not limited to the claimed invention.  Therefore, the Court found that the “Board’s redefinition…was a fundamental legal error.”  In finding the error not harmless, the Federal Circuit remanded the case back to the PTAB for review.[2]

This case is a single example of the less public ongoing battle streaming giants like Netflix and Hulu fight on a routine basis.  While there are standard essential patents (SEPs) vital to the compatibility of streaming technologies and devices that streaming providers license, there are third-parties who believe their streaming technology patents are being infringed behind-the-scenes.


[1] Netflix, Inc. v. DivX, LLC, IPR2022-1083 (PTAB Sept. 23, 2021)

[2] Netflix, Inc. v. DivX, LLC, No. 2022-1083, 2023 WL 2298768 (Fed. Cir. Mar. 1, 2023)